Maxim Group reissued their buy rating on shares of Adamis Pharmaceuticals (NASDAQ:ADMP) in a research report report published on Wednesday. Maxim Group currently has a $13.00 price objective on the specialty pharmaceutical company’s stock.

“The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced).”,” the firm’s analyst commented.

Other equities analysts have also recently issued reports about the stock. HC Wainwright set a $7.00 target price on shares of Adamis Pharmaceuticals and gave the company a buy rating in a research note on Monday, September 10th. B. Riley raised their target price on shares of Adamis Pharmaceuticals to $7.50 and gave the company a buy rating in a research note on Tuesday, July 3rd. Finally, Zacks Investment Research raised shares of Adamis Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, July 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $7.80.

NASDAQ:ADMP opened at $3.05 on Wednesday. Adamis Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $5.85. The company has a debt-to-equity ratio of 0.09, a quick ratio of 0.54 and a current ratio of 0.78.

Adamis Pharmaceuticals (NASDAQ:ADMP) last released its earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.10). Adamis Pharmaceuticals had a negative net margin of 240.92% and a negative return on equity of 88.96%. The firm had revenue of $3.92 million during the quarter, compared to the consensus estimate of $4.14 million. equities research analysts predict that Adamis Pharmaceuticals will post -0.78 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP acquired a new stake in Adamis Pharmaceuticals during the 1st quarter valued at $244,000. Northern Trust Corp lifted its holdings in Adamis Pharmaceuticals by 50.7% during the 1st quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock valued at $489,000 after purchasing an additional 46,924 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in Adamis Pharmaceuticals by 7.7% during the 2nd quarter. BlackRock Inc. now owns 293,328 shares of the specialty pharmaceutical company’s stock valued at $939,000 after purchasing an additional 20,871 shares during the last quarter. 8.41% of the stock is owned by institutional investors and hedge funds.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Read More: Trading Strategy Methods and Types

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.